TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03398083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: THC capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: THC capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: THC capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC
Description: THC capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Sugar pill capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Sugar pill capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Sugar pill capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Sugar pill capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Sugar pill capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD
Description: CBD capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD capsule
Study: NCT00850239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04320589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: 1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
Study: NCT00839319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg subcutaneous injections on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg subcutaneous injections on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg subcutaneous injections on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg subcutaneous injections on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg subcutaneous injections on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo hCG (no active ingredient)
Description: placebo hCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Description: 15 IU subcutaneous injection every other day for 10 days (5 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Description: 60 IU subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Description: 125 IU subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 75 mg testosterone gel applied transdermally for 10 days
Study: NCT05804617

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dome-type (Modified C-incision) manual morcellation
Description: Morcellation performed by surgeon or trainee

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dome-type (Modified C-incision) manual morcellation
Description: Morcellation performed by surgeon or trainee
Study: NCT00876551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum assisted closure
Description: 1. Endoscopic debridement of wound using a regular biopsy forceps.~2. Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~3. Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson \& Johnson, St-Stevens-Woluwe, Belgium).~4. Trimming of the sponge to the specific wound size.~5. Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~6. Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~7. Sponge exchange twice a week until wound grounds are clean and closed
Study: NCT00575640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
Study: NCT03005015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study: NCT01571518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: late leukostim
Description: injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: early leukostim
Description: injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Study: NCT00345748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Study: NCT02399163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride free toothpaste
Description: Brushing with fluoride free toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride free toothpaste
Description: Brushing with fluoride free toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Description: Brushing with fluoride containing toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Brushing with fluoride containing toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash
Description: Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash
Description: Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm
Study: NCT00433004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plan B (Levonorgestrel)
Description: PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
Study: NCT04860388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed eruption technique
Description: The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed eruption technique
Description: The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.
Study: NCT02225691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired testing of blood glucose Accu-Chek®
Description: Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
Study: NCT04097964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief intervention
Description: 1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: standard care conducted by primary care providers during clinic visits
Study: NCT01359085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISBPB - interscalene brachial plexus block
Description: ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
Study: NCT05337839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home exercises
Description: stretching, balance and strengthening exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home exercises
Description: stretching, balance and strengthening exercises
Study: NCT03128125

Intervention type: OTHER
Group type: OTHER
Intervention: clinical examination in neurology
Description: This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical examination in neurology
Description: This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological examination
Description: This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological examination
Description: This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.

Intervention type: OTHER
Group type: OTHER
Intervention: anamnestic elements
Description: Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anamnestic elements
Description: Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
Study: NCT01837823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
Study: NCT02238652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication
Description: A preparation process before the patient become incapable of participating in life prolonging decisions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Pain Assessment and Treatment
Description: Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Review
Description: An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety
Description: Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
Study: NCT01873534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-8
Description: FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-8
Description: FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-8
Description: FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
Study: NCT00823615

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use
Study: NCT03136848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normothermic ex-vivo kidney perfusion Solution -Toronto
Description: The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney.
Study: NCT01765972

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon
Description: contact lens with Lacreon

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon
Description: contact lens with Lacreon

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon
Description: contact lens with Lacreon

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon
Description: contact lens with Lacreon

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon with print
Description: contact lens with Lacreon and cosmetic print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon with print
Description: contact lens with Lacreon and cosmetic print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon with print
Description: contact lens with Lacreon and cosmetic print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon with print
Description: contact lens with Lacreon and cosmetic print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print
Description: contact lens with print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print
Description: contact lens with print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print
Description: contact lens with print

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print
Description: contact lens with print

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles (habitual)
Description: Spectacles

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles (habitual)
Description: Spectacles

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles (habitual)
Description: Spectacles

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles (habitual)
Description: Spectacles
Study: NCT01146743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gallbladder drainage
Description: EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous transhepatic gallbladder drainage
Description: Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
Study: NCT00955916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG Regimen
Description: The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec®
Description: Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
Study: NCT01934595

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beneprotein
Description: The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneprotein
Description: The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
Study: NCT00444145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevacid
Description: 30 mg bid for 3 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal and Laryngeal Biopsies
Description: repeat egd with biopsy after Prevacid 30 mg bid for 3 months
Study: NCT04271722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical ripening
Description: Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical ripening
Description: Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
Study: NCT03831451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke preparedness intervention
Description: Face-to-face interaction with research staff lasting between 5-10 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle stroke risk reduction intervention
Description: Face-to-face interaction with research staff lasting between 5-10 minutes